Company
Every investor coverage indicates participated in a round Royal Society Te Apārangi raised.
Companies Royal Society Te Apārangi acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Royal Society Te Apārangi. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brandon Capital led a NZ$14 million investment in Amaroq Therapeutics, a University of Otago spinout developing RNA cancer therapies, with three co-investors and a Callaghan Innovation repayable grant supporting the deal.
University of Otago cancer RNA spinout Amaroq Therapeutics has raised NZ$14 million led by Brandon Capital with Otago Innovation, NZ Innovation Booster and Cure Kids Ventures to advance its lncRNA-targeting cancer therapies.
Also Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio